Drug Approval | July 24, 2025
Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated
